Participating Organizations

The DAPT Study is an independent, large-scale study in size and scope intended to investigate the benefits of 12 versus 30 months of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents (DES).

The DAPT Study has achieved an unprecedented level of cooperation between regulators, academia and industry to answer a major public health question. The Study will be conducted through a public-private collaboration involving the Harvard Clinical Research Institute (HCRI), the U.S. Food and Drug Administration (FDA), four major stent manufacturers and the manufacturers of thienopyridine/antiplatelet medications.

The participating stent manufacturers are:

• Abbott (XIENCE®)
• Boston Scientific Corporation (TAXUS®, PROMUS®)
• Cordis Corporation (CYPHER®)
• Medtronic, Inc. (Endeavor®)

The manufacturers of the antiplatelet medications are:

• Bristol-Myers Squibb Company/Sanofi Pharmaceuticals Partnership (Plavix®(clopidogrel bisulfate))
• Eli Lilly and Company
• Daiichi Sankyo Company Limited (Effient™ prasugrel))

HCRI, a nonprofit academic research organization, was selected to oversee the scientific management of the DAPT Study and the independent analysis of the resulting data, and has received funding support from each of the drug and device manufacturers. The U.S. FDA will serve as the regulatory body of record for this trial.